Citations

Citations to this article as recorded by  

• Perioperative preparation for head and neck cancer patients receiving immunotherapy
  Shao-Chun Wu, Kuan-Hao Liao, Pi-Chieh Lin, Ching-Hua Hsieh
  Asian Journal of Surgery.2026; 49(2): 652.     CrossRef
• Risk factors of immune-related endocrine toxicities in non-small cell lung cancer patients treated with pembrolizumab and its impact on patient outcomes: a multicenter retrospective study
  Haoting Zhang, Jing Zheng, Chenyi Ren, Chenlin Ye, Xiaoyu Wu, Xiaodong Lv, Yuping Li, Jianya Zhou, Jianying Zhou
  BMC Pulmonary Medicine.2025;[Epub]     CrossRef
• Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
  Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
  BMC Cancer.2025;[Epub]     CrossRef
• Pembrolizumab-Induced Thyroid Storm in a Patient With Triple-Negative Breast Cancer
  Sobrina S. Mohammed, Eun Young Park, Reda Asad, Shourya Tadisina
  AACE Endocrinology and Diabetes.2025; 12(2): 107.     CrossRef
• Optimal Levothyroxine Dosing Strategy for Immune Checkpoint Inhibitor-related Hypothyroidism: A Retrospective Study
  Ya Gao, Chunxia Du, Yan Xu, Xinqi Cheng, Haitao Zhao, Fang Jiang, Ninghai Cheng, Yang Xiang, Yuelun Zhang, Yuanmeng Li, He Liu, Xiaofeng Chai, Xiaolan Lian, Weigang Zhao, Naishi Li
  The Journal of Clinical Endocrinology & Metabolism.2025; 110(12): 3342.     CrossRef
• Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report
  Xiaopeng Yu, Wenwen Zhao, Qingqing Feng, Jin Tian, Lili Zhao, Jun Xiao, Hongmei Wei
  Frontiers in Oncology.2025;[Epub]     CrossRef
• Changes in thyroid hormone levels indicate immunotherapy efficacy in gastric cancer
  Min Xiao, Lan Qian, Qiu Zhao, Jian Ma, Qianxiao Li, Qian Liu, Zhiyan Bi
  Oncology Letters.2025; 30(1): 1.     CrossRef
• Development and validation of a nomogram for predicting immune-related thyroid dysfunction during immunotherapy in non-small cell lung cancer: a prospective cohort study in China
  Qianjie Xu, Yuliang Yuan, Xiaosheng Li, Lulu Wang, Wei Zhou, Zuhai Hu, Haike Lei, Yongzhong Wu
  Frontiers in Immunology.2025;[Epub]     CrossRef
• Incidence of thyroid adverse events following immune checkpoint inhibitor treatment in patients with baseline positive thyroid antibodies: a systematic review and meta-analysis
  Hui Yu, Qichao Chen, Wenbing Hu, Yuanhao Chen, Hui Ming
  Frontiers in Oncology.2025;[Epub]     CrossRef
• Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors
  Nicola Marrano, Mariangela Caporusso, Carlo Ganini, Andrea Borraccino, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Camillo Porta, Francesco Giorgino, Annalisa Natalicchio
  Journal of Endocrinological Investigation.2025; 49(2): 399.     CrossRef
• Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
  Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
  Liver Cancer.2024; 13(1): 89.     CrossRef
• Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
  Yanling Wang, Xiaoxuan Yang, Jia Ma, Shenglan Chen, Ping Gong, Ping Dai
  Heliyon.2024; 10(5): e27077.     CrossRef
• Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
  Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, Dhruv Bansal
  Cancers.2024; 16(6): 1225.     CrossRef
• Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
  Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima
  Endocrine Journal.2024; 71(5): 515.     CrossRef
• Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma
  Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman, Theo Rispens, Els M E Verdegaal, Dirk J A R Moes, Catharina M Korse, Ellen Kapiteijn, Marij J P Welters, Sjoerd H van der Burg, Winan J van Houdt, Johannes V van Thienen, John B A G Haanen, Dia
  Journal for ImmunoTherapy of Cancer.2024; 12(6): e009215.     CrossRef
• Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy
  Qian Wang, Tingting Wu, Ru Zhao, Yuanqin Li, Xuetao Chen, Shanmei Shen, Xiaowen Zhang
  Endocrine Practice.2024; 30(10): 943.     CrossRef
• Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial
  Yan Zheng, Guanghui Liang, Dongfeng Yuan, Xianben Liu, Yufeng Ba, Zimin Qin, Sining Shen, Zhenxuan Li, Haibo Sun, Baoxing Liu, Quanli Gao, Peng Li, Zongfei Wang, Shilei Liu, Jianping Zhu, Haoran Wang, Haibo Ma, Zhenzhen Liu, Fei Zhao, Jun Zhang, He Zhang,
  Cancer Communications.2024; 44(10): 1214.     CrossRef
• Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction
  Jinyu Liu, Mengli Chen, Shu Li, Le Cai, Liang Ma, Qiuliang Yang, Xiaoxuan Zhang, Nan Bai, Xiaodong Wu, Zhihui Tang, Tianlin Wang
  Frontiers in Immunology.2024;[Epub]     CrossRef
• Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
  Xinya Li, Zaiwei Song, Yixuan Chen, Jingjing Wu, Dan Jiang, Zhen Zhang, Zeyuan Wang, Rongsheng Zhao
  Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
• Serologic predictors of thyroid immune-related adverse events during immune checkpoint inhibitors therapy: a retrospective cohort study
  Anastasia A. Glibka, Natalia V. Mazurina, Ksenia A. Sarantseva, Galina Y. Kharkevich, Mikhail V. Volkonskii, Alina R. Elfimova, Ekaterina A. Troshina
  Almanac of Clinical Medicine.2024; 52(7): 385.     CrossRef
• Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
  David Dora, Syeda Mahak Zahra Bokhari, Kenan Aloss, Peter Takacs, Juliane Zsuzsanna Desnoix, György Szklenárik, Patrick Deniz Hurley, Zoltan Lohinai
  International Journal of Molecular Sciences.2023; 24(3): 2769.     CrossRef
• Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
  Xiangxiao Hu, Lina Wang, Bin Shang, Junren Wang, Jian Sun, Bin Liang, Lili Su, Wenjie You, Shujuan Jiang
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
  Yong-Zhe Hou, Qin Zhang, Hai Bai, Tao Wu, Ya-Jie Chen
  World Journal of Clinical Cases.2023; 11(7): 1458.     CrossRef
• Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
  Iñigo Les, Mireia Martínez, Inés Pérez-Francisco, María Cabero, Lucía Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Iñaki Elejalde, Grazyna Kochan, David Escors
  Cancers.2023; 15(5): 1629.     CrossRef
• Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience
  Alice Nervo, Matteo Ferrari, Giovanni Gruosso, Enrica Migliore, Sara Basile, Valentina D’Angelo, Anna Roux, Alessandro Piovesan, Emanuela Arvat
  Clinical and Experimental Medicine.2023; 23(8): 4817.     CrossRef
• RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies
  Rena Pollack, Joshua Stokar, Natan Lishinsky, Irina Gurt, Naomi Kaisar-Iluz, Merav E. Shaul, Zvi G. Fridlender, Rivka Dresner-Pollak
  International Journal of Molecular Sciences.2023; 24(13): 10526.     CrossRef
• Immune‐related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity
  Namrata Singh, Anne M. Hocking, Jane H. Buckner
  Immunological Reviews.2023; 318(1): 81.     CrossRef
• Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
  Nicia I. Profili, Roberto Castelli, Antonio Gidaro, Alessandro Merella, Roberto Manetti, Giuseppe Palmieri, Margherita Maioli, Alessandro P. Delitala
  Journal of Clinical Medicine.2023; 12(15): 5161.     CrossRef
• Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
  Won Sang Yoo, Eu Jeong Ku, Eun Kyung Lee, Hwa Young Ahn
  Endocrinology and Metabolism.2023; 38(6): 750.     CrossRef
• PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
  Ke Zhang, Xiangyi Kong, Yuan Li, Zhongzhao Wang, Lin Zhang, Lixue Xuan
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients
  Han-sang Baek, Chaiho Jeong, Kabsoo Shin, Jaejun Lee, Heysun Suh, Dong-Jun Lim, Moo Il Kang, Jeonghoon Ha
  BMC Endocrine Disorders.2022;[Epub]     CrossRef
• A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events
  Hidemi Hayashi, Koji Sawada, Takumu Hasebe, Shunsuke Nakajima, Jun Sawada, Yuri Takiyama, Yumi Takiyama, Toshikatsu Okumura, Mikihiro Fujiya
  Internal Medicine.2022; 61(23): 3497.     CrossRef
• Immune Related Adverse Events of the Thyroid – A Narrative Review
  Christopher A. Muir, Venessa H. M. Tsang, Alexander M. Menzies, Roderick J. Clifton-Bligh
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Thyroid-related adverse events induced by immune checkpoint inhibitors
  Alexandra Chera, Andreea Lucia Stancu, Octavian Bucur
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
  Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, Carolyn J. Presley, Ashish Manne
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Case 5: A 41-Year-Old Woman With Palpitation
  Jiwon Yang, Kabsoo Shin, Jeongmin Lee, Jeonghoon Ha, Dong-Jun Lim, Han-Sang Baek
  Journal of Korean Medical Science.2022;[Epub]     CrossRef
• Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
  Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim
  Endocrinology and Metabolism.2022; 37(6): 839.     CrossRef
• Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
  Calogera Claudia Spagnolo, Giuseppe Giuffrida, Salvatore Cannavò, Tindara Franchina, Nicola Silvestris, Rosaria Maddalena Ruggeri, Mariacarmela Santarpia
  Cancers.2022; 15(1): 246.     CrossRef
• Antineoplastics
  
  Reactions Weekly.2021; 1874(1): 31.     CrossRef